WHO ships free child cancer medicines

GENEVA, Switzerland (AFP) — The World Health Organization (WHO) launched on Tuesday a new platform providing cost-free cancer medicines for thousands of children living in low- and middle-income countries, in a bid to improve lagging survival rates.

The first medicines were being delivered to Mongolia and Uzbekistan, the WHO said, with further shipments planned for Ecuador, Jordan, Nepal and Zambia, as part of the project’s pilot phase.

The treatments are expected to reach around 5,000 children with cancer this year across at least 30 hospitals in those six nations.

“Countries in the pilot phase will receive an uninterrupted supply of quality-assured childhood cancer medicines at no cost,” the United Nations health agency said in a statement.

The WHO said that childhood cancer survival rates in low- and middle-income countries were often below 30 percent, compared with around 80 percent in high-income countries.

“For too long, children with cancer have lacked access to life-saving medicines,” WHO chief Tedros Adhanom Ghebreyesus said.

A further six countries have been invited to join the platform, which hopes to reach 50 countries in the next five to seven years, providing medicines for approximately 120,000 children.

An estimated 400,000 children worldwide develop cancer every year, most of them living in resource-limited settings, the WHO said.

“It is estimated that 70 percent of the children from these settings die from cancer due to factors such as lack of appropriate treatment, treatment disruptions or low-quality medicines,” it said.

The WHO said cost-free provision would continue beyond the pilot phase, and the platform is working on developing its sustainability over the longer term.

The plan to establish the platform was first announced in December 2021.

It is a joint enterprise between the WHO and St. Jude Children’s Research Hospital in Memphis, Tennessee in the United States.

The non-profit paediatric treatment and research institution has committed $200 million to its launch, the WHO said.